about
Recombinant protein quality evaluation: proposal for a minimal information standardMolecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma - a case reportPML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias.Comparative expressed sequence hybridization studies of high-hyperdiploid childhood acute lymphoblastic leukemia.AML1/ETO accelerates cell migration and impairs cell-to-cell adhesion and homing of hematopoietic stem/progenitor cells.Nucleophosmin leukemogenic mutant activates Wnt signaling during zebrafish development.The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha.Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP RegimenRecurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridizationAdhesion Deregulation in Acute Myeloid LeukaemiaUnderstanding the molecular basis of acute myeloid leukemias: where are we now?[The frequency of cytomegalovirus infection (CMV) in patients immunocompromised patients with malignant and nonmalignant blood disorders][Apoptosis (programmed cell death) in the immune system and hemopoiesis][Erythro-tropic human parvovirus B19 (HPV)]The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridizationp53 abnormalities in splenic lymphoma with villous lymphocytesCharacterisation of TP53 abnormalities in chronic lymphocytic leukaemiaUnusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion geneDeletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytesDelineation of the minimal region of loss at 13q14 in multiple myelomaA monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemiasThe concurrent use of N- and C-terminal antibodies anti-nucleophosmin 1 in immunofluorescence experiments allows for precise assessment of its subcellular localisation in acute myeloid leukaemia patientsConsolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up.Wnt Signalling in Acute Myeloid LeukaemiaHas Drug Repurposing Fulfilled its Promise in Acute Myeloid Leukaemia?
P50
Q28741633-561F652B-75BA-43E6-BD06-6B1104FE4826Q36123511-0E0383AA-D28E-4961-9F3C-D0618E8EF88AQ38438690-F0F40D13-87F8-436E-A631-2B80AE44C157Q38521676-E3038C83-B3CC-444C-B5DA-73DB0549F403Q38742142-311B74AA-0B6E-45B4-AECF-E18201007E20Q38754098-4F0FDD1A-546E-4124-B8DA-0B5957F44811Q53289991-A2384101-1A1B-4F08-9897-F33B215AE5F5Q58101866-DA92BF98-25A9-4A56-83EC-B4EFB73C5B7EQ59194347-FAC85213-84EE-47A3-AFBE-CDB2C67302E8Q61813975-CBA914BF-157C-441C-8728-C84035048727Q64942073-45A0FD70-76F7-4F03-A676-054048823374Q71076258-692B87D4-2398-41C1-A129-28886E509AD8Q72523619-D7D89BB3-2833-4401-9BFA-BF71731FF8FDQ72629787-3C0CA1CE-736F-4241-976C-CEF6E479090FQ73129799-79E7146B-6ACC-4986-B57A-599AEF230A3BQ73919458-C53ED895-9088-4507-9BBB-2538F178D848Q75339454-4B77088D-0FA2-4202-A845-260206EC913AQ77495202-4662E1C4-91F9-407C-8DBE-0B6103AE8AE7Q78600344-85106CE9-2D30-4F98-AE48-5ACA9C43D0AFQ78600352-DD89A0FD-925D-453D-BD6B-F21A84D6E0B1Q84386374-C4198B79-6597-48B7-85ED-BCA6BA7BF0F6Q84583451-24A66CA9-A057-48AE-989A-35523044B03FQ91013242-AC0A70EE-9813-4DFB-932E-1C7C7FDDA122Q91190930-73AF7321-91C9-4F42-BBF1-B6303B6B084AQ96604429-6CBAAF6C-51EC-4918-BDA1-A07912DBF8C5
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alicja M Gruszka
@ast
Alicja M Gruszka
@en
Alicja M Gruszka
@es
Alicja M Gruszka
@nl
type
label
Alicja M Gruszka
@ast
Alicja M Gruszka
@en
Alicja M Gruszka
@es
Alicja M Gruszka
@nl
prefLabel
Alicja M Gruszka
@ast
Alicja M Gruszka
@en
Alicja M Gruszka
@es
Alicja M Gruszka
@nl
P106
P1153
6602918125
P31
P496
0000-0002-5359-0281